Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms-Reference-Cited by-同舟云学术

Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms

Published:2006-01-20 Issue:4 Volume:61 Page:440-450
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Bernsdorf Annika,Giessmann Thomas,Modess Christiane,Wegner Danilo,Igelbrink Stefanie,Hecker Ute,Haenisch Sierk,Cascorbi Ingolf,Terhaag Bernd,Siegmund Werner

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2006.02599.x/fullpdf

Reference38 articles.

1. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man;Trausch;Biopharm Drug Dispos,1995

2. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers. concentration- and dose-dependent absorption in vitro and in vivo;Wetterich;Pharm Res,1996

3. Talinolol-verapamil interaction is not solely due to p-glycoprotein inhibition;Schwarz;Clin Pharmacol Ther,2001

4. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound;Spahn-Langguth;Int J Clin Pharmacol Ther,1998

5. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans;Gramatte;Clin Pharmacol Ther,1996

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into Intestinal P-glycoprotein Function using Talinolol: A PBPK Modeling Approach;2023-11-22

2. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney;CPT: Pharmacometrics & Systems Pharmacology;2022-06-06

3. Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P‐Glycoprotein;The Journal of Clinical Pharmacology;2021-01-29

4. The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins;International Journal of Molecular Sciences;2020-11-19

5. Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics;Xenobiotica;2019-06-24